NCT02521363 2025-08-22
Implantable Microdevice for In Vivo Drug Sensitivity Testing in Patients With Early Stage, HER2-Positive or Triple Negative Breast Cancer
Memorial Sloan Kettering Cancer Center
Phase NA Completed
Memorial Sloan Kettering Cancer Center
Bristol-Myers Squibb
Novartis
Teva Branded Pharmaceutical Products R&D, Inc.
Kronos Bio
Merck Sharp & Dohme LLC
AstraZeneca